Results of Low-Dose Cytosine Arabinoside and Aggressive Chemotherapy in Patients with Advanced Myelodysplastic Syndromes
As known from recent studies [7, 8], advanced myelodysplastic syndromes (MDS) are characterized by a poor prognosis. Within 2 years of diagnosis most patients die of infections or hemorrhagic complications related to bone marrow failure or development of acute leukemia. Despite a number of clinical trials no generally accepted form of treatment exists for this syndrome . Based on earlier reports, aggressive antileukemic regimens have been regarded as ineffective or even dangerous because of the risk of severe and prolonged aplasia . During the past decade, many authors have concentrated on the use of low-dose cytosine arabinoside (ara-C), but published data are difficult to compare due to varying doses and schedules in the administration of ara-C .
KeywordsToxicity Leukemia Oncol Thrombocytopenia Stein
Unable to display preview. Download preview PDF.
- 5.Büchner Th, Urbanitz D, Brücher H, Heinecke A, Hiddemann W, Rühl H, Schulte H, Wendt F (1984) Chemotherapie der akuten myeloischen Leukämie des Erwachsenen. In: Büchner Th, Urbanitz D, Van De Loo J (eds) Therapie der akuten Leukämien. Springer, Berlin Heidelberg New York, pp 59–71Google Scholar
- 6.Cheson BD, Jasperse DM, Simon R, Friedman MA (1986) A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 12: 1857–1864Google Scholar
- 9.Lazzarino M, Mona E, Inverardi D, Alessandrino EP, Castelli G, Bernasconi P, Castagnola C, Bernasconi C (1986) Combined etoposide (VP-16) and cytarabine (ara-C) for acute myelogenous le ukemias (AML) evolving from myelodysplastic syndromes (MDS) or secondary to treatment for malignant diseases ( MD ). Proc Am Soc Clin Oncol 5: 161Google Scholar